

Application Serial No.: 10/068,725
Amendment dated: February 27, 2006
Response to Office Action dated September 1, 2005

4

REMARKS

Reconsideration of the application in view of the above amendments and following remarks is requested. The Examiner is thanked for the grant of the telephonic interview of February 27, 2006. Claims 1 and 10 have been amended in accordance with this interview. New claims 25-29 have been added. Support for these amendments and the new claims can be found at least at page 4, lines 10-26 and page 6, line 33 – page 7, line 2 of the present specification. Accordingly, no new matter has been added with these claim amendments.

Claims 1-8, 10, and 24-29 are currently pending.

I. Rejection under 35 U.S.C. § 112, first paragraph

The present claims have been amended to direct the epitope description to binding the TACI molecule and to indicate that the antibody component of claims 10 and 25 are in addition to the anti-BCMA-TACI antibody components of claim 1. It is believed that these claim amendments overcome the new matter and written description issues of the previous Office Action and withdrawal of this rejection is therefore respectfully requested.

On the basis of the above amendments and remarks, Applicants believe that each rejection has been addressed and overcome. Reconsideration of the application and its allowance are requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6627.

Respectfully Submitted,

Michelle L Lewis

Michelle L. Lewis
Registration No. 36,352

Enclosures:

Notice of Appeal (in duplicate)
Petition and Fee for Extension of Time (in duplicate)
Amendment Fee Transmittal (in duplicate)